Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
Crossref DOI link: https://doi.org/10.1186/s12944-016-0227-2
Published Online: 2016-03-12
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Glueck, Charles J.
Shah, Parth
Goldenberg, Naila
Prince, Marloe
Lee, Kevin
Jetty, Vybhav
Kumar, Ashwin
Goldenberg, Michael
Wang, Ping
Funding for this research was provided by:
Lipoprotein Research Fund of the Jewish Hospital of Cincinnati